Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3800212 | 0.90 | TSHR (0.36) | TSHRTDP1ALDH1A1HSD17B10 | |
| SCHEMBL303730 | 0.88 | TSHR (0.44) | TSHRTDP1ALDH1A1HSD17B10 | |
| SCHEMBL5689894 | 0.87 | TSHR (0.42) | TSHRTDP1ALDH1A1HSD17B10 | |
| SCHEMBL542901 | 0.83 | TSHR (0.35) | TSHRTDP1ALDH1A1HSD17B10SOAT1 | |
| SCHEMBL1333110 | 0.80 | TSHR (0.40) | TSHRTDP1ALDH1A1HSD17B10 | |
| SCHEMBL12688305 | 0.80 | ALDH1A1 (0.40) | TSHRTDP1ALDH1A1HSD17B10 | |
| SCHEMBL8626720 | 0.80 | TSHR (0.40) | TSHRTDP1ALDH1A1HSD17B10 | |
| Ethylene SCHEMBL31265746 | 0.79 | TSHR (0.32) | TSHRTDP1ALDH1A1HSD17B10 | |
| Ethylene SCHEMBL31265739 | 0.79 | TSHR (0.32) | TSHRTDP1ALDH1A1HSD17B10 | |
| SCHEMBL3920190 | 0.78 | TSHR (0.39) | TSHRTDP1ALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 147 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116751241-A | Preparation and application of 2' -deoxy-2 ',2' -difluoro cytidine ProTide | 杭州爱科瑞思生物医药有限公司 | 2023-09-15 | — | — | CN | claimed |
| US-20130102811-A1 | PROCESS FOR THE PREPARATION OF LACOSAMIDE | SUN PHARMACEUTICAL INDUSTRIES LTD (IN) | 2013-04-25 | — | — | US | claimed |
| US-20240216357-A1 | POLYCYCLIC COMPOUND AND APPLICATION THEREOF | SICHUAN HUIYU PHARMACEUTICAL CO., LTD. (CN) | 2024-07-04 | — | — | US | disclosed |
| EP-3768888-B1 | COMPOSITE MATERIALS | UEA ENTERPRISES LTD (GB) | 2024-05-01 | — | — | EP | disclosed |
| CN-116751240-A | Preparation and application of 2' -deoxy-2 ',2' -difluoro cytidine carbonate hydrazide | 杭州爱科瑞思生物医药有限公司 | 2023-09-15 | — | — | CN | disclosed |
| CN-116751241-A | Preparation and application of 2' -deoxy-2 ',2' -difluoro cytidine ProTide | 杭州爱科瑞思生物医药有限公司 | 2023-09-15 | — | — | CN | disclosed |
| CN-113278166-B | Dissolving regeneration and stable dispersion system of single-molecule cellulose | 青岛量子元基环保科技有限公司 | 2023-06-16 | — | — | CN | disclosed |
| US-20210147642-A1 | COMPOSITE MATERIALS | UEA ENTERPRISES LIMITED (GB) | 2021-05-20 | — | — | US | disclosed |
| EP-3768888-A1 | COMPOSITE MATERIALS | UEA Enterprises Limited (GB) | 2021-01-27 | — | — | EP | disclosed |
| US-10864279-B2 | Linker-drug and antibody-drug conjugate (ADC) employing the same | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2020-12-15 | — | — | US | disclosed |
| US-20180169262-A1 | LINKER-DRUG AND ANTIBODY-DRUG CONJUGATE (ADC) EMPLOYING THE SAME | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2018-06-21 | — | — | US | disclosed |
| WO-1996022997-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 1996-08-01 | — | — | WO | disclosed |
| WO-1996006849-A1 | NOVEL PHOSPHANE OXIDES, METHOD OF PREPARING THEM AND DRUGS CONTAINING THESE COMPOUNDS | BOEHRINGER MANNHEIM GMBH (DE) | 1996-03-07 | — | — | WO | disclosed |
| EP-0343893-B1 | AROMATIC AND HETEROCYCLIC CARBOXAMIDE DERIVATIVES AS ANTINEOPLASTIC AGENTS | PFIZER INC. (US) | 1992-08-05 | — | — | EP | disclosed |
| US-4970318-A | ANTICARBINOGENIC AGENTS | PFIZER INC. (US) | 1990-11-13 | — | — | US | disclosed |
| US-4904680-A | IMMUNOLOGY | SANKYO COMPANY, LIMITED (JP) | 1990-02-27 | — | — | US | disclosed |
| EP-0173441-B1 | AMINO ACID DERIVATIVES HAVING ANTI-TUMOR ACTIVITY AND COMPOSITIONS CONTAINING THEM | SANKYO COMPANY LIMITED (JP) | 1990-01-24 | — | — | EP | disclosed |
| EP-0328585-A1 | METABOLICALLY ACCEPTABLE POLYISOCYANATE ADHESIVES | BIORESEARCH INC. (US) | 1989-08-23 | — | — | EP | disclosed |
| US-4806655-A | Process for the stereospecific synthesis of indole derivatives | SOCIETE ANONYME: SANOFI (FR) | 1989-02-21 | — | — | US | disclosed |
| EP-0173441-A1 | Amino acid derivatives having anti-tumor activity and compositions containing them | SANKYO COMPANY LIMITED (JP) | 1986-03-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130102811-A1 | PROCESS FOR THE PREPARATION OF LACOSAMIDE | SLC6A11, CACNA1B, SLC6A1 | TSHR 2361/4885TDP1 2128/4885ALDH1A1 1393/4885 |
| US-20180169262-A1 | LINKER-DRUG AND ANTIBODY-DRUG CONJUGATE (ADC) EMPLOYING THE SAME | ADCY7, ADCY1, ADCY9 | TSHR 411/4885TDP1 4151/4885ALDH1A1 716/4885 |
| US-10864279-B2 | Linker-drug and antibody-drug conjugate (ADC) employing the same | ADCY7, ADCY1, ADCY9 | TSHR 411/4885TDP1 4151/4885ALDH1A1 716/4885 |
| US-20240216357-A1 | POLYCYCLIC COMPOUND AND APPLICATION THEREOF | KDM1A, TET1, KDM3A | TSHR 4378/4885TDP1 275/4885ALDH1A1 460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.